These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3068036)

  • 1. Octreotide: a synthetic analog of somatostatin.
    Rosenberg JM
    Drug Intell Clin Pharm; 1988 Oct; 22(10):748-54. PubMed ID: 3068036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
    Battershill PE; Clissold SP
    Drugs; 1989 Nov; 38(5):658-702. PubMed ID: 2689136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debut of a somatostatin analog: octreotide in review.
    Zindel LR
    Conn Med; 1989 Dec; 53(12):741-4. PubMed ID: 2558839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
    Harris AG
    Gut; 1994; 35(3 Suppl):S1-4. PubMed ID: 7911441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
    Ludlam WH; Anthony L
    Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide, a new somatostatin analogue.
    Katz MD; Erstad BL
    Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
    Gillis JC; Noble S; Goa KL
    Drugs; 1997 Apr; 53(4):681-99. PubMed ID: 9098666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of acromegaly with octreotide, a synthetic analog of somatostatin with extended action].
    Arosio M; Bazzoni N; Faglia G
    Minerva Endocrinol; 1990; 15(1):29-36. PubMed ID: 2274011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
    Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
    Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Somatostatin analog (octreotide) in clinical use: current and potential indications].
    Meier R; Dierdorf R; Gyr K
    Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors].
    Chanson P; Timsit J; Harris AG
    Presse Med; 1993 Dec; 22(40):2009-16. PubMed ID: 7907419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.
    Biermasz NR; Pereira AM; Frölich M; Romijn JA; Veldhuis JD; Roelfsema F
    Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E25-30. PubMed ID: 14506078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
    Freda PU; Katznelson L; van der Lely AJ; Reyes CM; Zhao S; Rabinowitz D
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice.
    Maggio ET; Grasso P
    Regul Pept; 2011 Apr; 167(2-3):233-8. PubMed ID: 21329733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.